What Is Pramlintide?

1. What Is Amylin, the Hormone Behind the Drug?

Every time beta cells in the pancreas release insulin after a meal, they release a second hormone with it: amylin, a 37-amino-acid peptide also called islet amyloid polypeptide, or IAPP. Insulin handles the sugar already in the blood. Amylin works on the pace at which more sugar arrives, slowing how fast the stomach empties, suppressing the glucagon signal that tells the liver to release stored sugar after eating, and contributing to the feeling of having eaten enough (SymlinPen label).

People with type 1 diabetes have lost the beta cells that make both hormones, so they are missing amylin as well as insulin. That observation is what created the drug: if you replace one beta-cell hormone, why not the other?

Amylin is not a GLP-1. GLP-1 is made in the gut wall in response to food and acts on its own receptor; amylin comes from the pancreas and acts on amylin receptors in the brainstem. The two pathways produce overlapping effects on appetite through different machinery, which is the whole reason the drug industry is now interested in running both at once.

2. Why Can’t You Just Inject Amylin?

Because human amylin destroys itself. The natural peptide readily clumps into amyloid fibrils, the same sticky deposits found in the pancreatic islets of people with type 2 diabetes. A hormone that aggregates in the vial is not a drug, and the aggregates are toxic to the very cells the hormone comes from.

Rat amylin does not do this. Comparing the two sequences shows the difference sits in a short stretch in the middle, and pramlintide was built by taking the human sequence and swapping in three prolines from the rat version, at positions 25, 28 and 29, replacing an alanine and two serines. Proline is the amino acid that kinks a chain and refuses to sit flat, so those three substitutions block the beta-sheet stacking that fibrils are made of, without changing how the peptide binds its receptor (SymlinPen label, amylin pharmacology review).

The fix was partial. Pramlintide still has to be kept in an acidic solution to stay dissolved, which is why the label forbids mixing it with insulin in the same syringe: combining them changes how both are absorbed. Every amylin analog since has had to solve this same stability problem, and the modern ones solve it better. Zealand Pharma designed petrelintide to stay stable at neutral pH precisely so it can share a syringe with other peptides.

3. What Did Pramlintide Actually Do?

The label describes three actions, all aimed at the hours after a meal rather than at fasting glucose:

The gastric-emptying effect is strong enough to have its own instruction: any oral medication that needs to be absorbed quickly, such as a painkiller, an antibiotic, or an oral contraceptive, had to be taken at least an hour before or two hours after a pramlintide injection (SymlinPen label).

4. What Did the Trials Show?

Pramlintide worked. It just did not work dramatically.

In insulin-treated type 2 diabetes, a meta-analysis of four trials in 930 patients found a placebo-corrected HbA1c reduction of 0.33 percentage points and weight loss of 2.57 kg. Across four obesity trials in 686 participants without diabetes, weight fell 2.27 kg more than placebo (meta-analysis).

The most informative study was a 16-week Phase 2 trial that pushed the dose higher than the diabetes label allowed. It gave 204 adults with an average BMI of 37.8 up to 240 mcg three times daily, with no lifestyle program attached. Participants who completed it lost 3.7% more than placebo, about 3.6 kg, and 3.6 cm from the waist (obesity dose-escalation trial).

Two details from that obesity trial are worth keeping. Dose mattered: the higher, three-times-daily regimen produced roughly three times the responder rate seen at the diabetes dose. And the weight loss was not simply people being too nauseated to eat, because participants who never reported nausea lost the same amount as those who did, 3.6% against 3.9% (obesity trial).

For scale, semaglutide and tirzepatide produce 15% to 20% weight loss in their trials. Pramlintide’s 3% to 4% is real, reproducible pharmacology, and nowhere near enough to compete on its own.

5. How Was It Dosed, and Why Was That Hard?

Pramlintide was an injection before every major meal, on top of insulin, and never mixed with it. The label started people with type 1 diabetes at 15 mcg and worked up in 15 mcg steps to 30 or 60 mcg; people with type 2 diabetes started at 60 mcg and moved to 120 mcg. Critically, mealtime insulin had to be cut by 50% on the day pramlintide started (SymlinPen label).

That last instruction is why the drug carries a boxed warning for severe hypoglycemia. Pramlintide does not lower blood sugar much by itself; it makes the insulin already on board hit differently. If insulin is not reduced, blood sugar can crash, and the label notes that when severe hypoglycemia happened it appeared within three hours of the injection. The drug is contraindicated in people with confirmed gastroparesis, whose stomachs are already emptying too slowly, and in people with hypoglycemia unawareness, who would not feel the crash coming.

Tolerability was the other obstacle. In type 1 diabetes trials, nausea was reported by 48% of pramlintide users against 17% on placebo, with anorexia at 17% and vomiting at 11%. In type 2 diabetes the numbers were lower, 28% nausea against 12% (SymlinPen label).

6. Who Made It, and Why Was It Discontinued?

Pramlintide came from Amylin Pharmaceuticals, a San Diego company built around this single hormone. The FDA approved Symlin under NDA 21-332 on March 16, 2005, after a long review that included an approvable letter in 2001 and additional clinical work (FDA approval letter). Amylin was bought by Bristol-Myers Squibb in 2012, and AstraZeneca subsequently took full ownership of the former Amylin products (AstraZeneca announcement).

openFDA drug shortage data lists both SymlinPen 60 and SymlinPen 120 from AstraZeneca AB with a discontinued date of October 27, 2025, and the FDA application record now shows the Symlin products as discontinued (openFDA data).

Nothing in that record describes a safety withdrawal. Discontinuation is a business decision about manufacturing and demand, and the demand was never large: a mealtime injection with a boxed warning, an insulin dose reduction, and a nausea rate near 50% is a hard product to prescribe when the alternative is a once-weekly GLP-1.

7. Why Pramlintide Still Matters

Pramlintide proved that the amylin pathway does something useful in humans, that a stabilized analog can be given safely, and that the effect is on appetite rather than only on glucose. Then it sat alone for twenty years, because nobody had solved the delivery problem.

The current generation exists to fix exactly the things that held pramlintide back. Where pramlintide needed three injections a day, these are once weekly. Where pramlintide’s acidic formulation could not share a syringe with anything, several of these were engineered to be co-formulated with a GLP-1:

The reasoning behind all of them traces back to pramlintide’s trials: amylin reduces food intake through a route that does not depend on the GLP-1 receptor, so adding it to a GLP-1 drug should add weight loss rather than duplicate it. That hypothesis is now being tested at scale in trials involving tens of thousands of people.

8. Pramlintide Versus the Drugs People Compare It To

Pramlintide is regularly mistaken for a GLP-1 because it is an injectable peptide for diabetes that reduces appetite and causes nausea. The label is explicit that it is an amylin analog, and that distinction matters when reading about newer drugs: semaglutide and tirzepatide are incretin drugs, while cagrilintide and petrelintide are pramlintide’s actual descendants. For the brand-side detail on the product itself, including package strengths and label history, see What Is Symlin?.

9. Pramlintide FAQ

• What is pramlintide in simple terms?

  It is a lab-made copy of amylin, a hormone your pancreas releases with insulin at every meal. Amylin tells the stomach to empty more slowly, stops the liver being told to release extra sugar, and contributes to feeling full. Pramlintide was given as an injection before meals to add that missing signal back for people using insulin.

• Is pramlintide a GLP-1?

  No. GLP-1 comes from the gut and amylin comes from pancreatic beta cells, and they act on different receptors. Pramlintide is labeled an amylin analog. The two pathways overlap in what they do, which is why several companies are now combining an amylin drug with a GLP-1 drug in one injection.

• Is pramlintide still available?

  AstraZeneca listed SymlinPen 60 and SymlinPen 120 as discontinued in openFDA drug shortage data with a date of October 27, 2025, and the FDA application now shows the products as discontinued. Discontinuation was a commercial and supply decision, not a safety withdrawal.

• How much weight did people lose on pramlintide?

  In insulin-treated type 2 diabetes, a meta-analysis found about 2.6 kg more than placebo. In a 16-week obesity trial using higher doses, people who completed treatment lost 3.7% more than placebo, and 31% of them lost at least 5% of body weight against 2% on placebo. That is far below what modern GLP-1 medicines achieve.

• Why did pramlintide never become a weight-loss blockbuster?

  The practical burden was heavy. It was a separate injection before every major meal, it could not be mixed with insulin in the same syringe, its label required halving mealtime insulin at the start, and it carried a boxed warning for severe hypoglycemia. Roughly half of type 1 patients in trials reported nausea. Weekly amylin analogs were designed to remove exactly these problems.

10. Sources